Spritam Tablet, For Suspension
Product Images NDC 43485-101

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Spritam (NDC 43485-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aprecia Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Recommended Dosage Adjustment Formula (Spritam 01)

The given text describes a formula to calculate the estimated glomerular filtration rate (eGFR) for a patient. It involves multiplying the quantity of 140 minus the patient's age in years, with the weight of the patient in kilograms. This result is then multiplied by 0.85 for female patients. The next step involves multiplying the answer obtained in the first step with the patient's serum creatinine level in mg/dL. The value of 72 is also used in this calculation.*

FDA Label Image

Recommended Dosage Adjustment Formula (Spritam 02)

This appears to be a table with three columns containing abbreviations and units of measurement. The first column has the heading "CLer (mL/min)", the second column has the heading "CLer (mU/min/1.73m?)", and the third column has the heading "BSA subject (m?)". Without more context, it is difficult to determine the purpose or meaning of these measurements.*

FDA Label Image

Imprint Marking (Spritam 03)

FDA Label Image

Imprint Marking (Spritam 04)

FDA Label Image

Imprint Marking (Spritam 05)

FDA Label Image

Imprint Marking (Spritam 06)

FDA Label Image

Chemical Structure (Spritam 07)

FDA Label Image

Figure 1 (Spritam 08)

This appears to be a graph showing the percentage of patients at different levels of medication dosage for Placebo and Levetiracetam. However, without a visual representation of the graph or further context, it is difficult to provide a more specific description.*

FDA Label Image

Figure 2 (Spritam 09)

This appears to be a table showing percentages of three different treatments: Placcbo, Levetiracetam at 1000mg/day, and Levetiracetam at 2000mg/day. However, without additional context, it is not clear what these percentages represent or what they relate to.*

FDA Label Image

Figure 3 (Spritam 10)

This text likely describes the effectiveness of two different treatments, Placebo and Levetiracetam, with a sample size of 104 and 180 respectively. The numbers 39.4% and 14.4% may relate to the reduction in symptoms or improvement in the condition for each treatment. However, without more context, it is difficult to determine the exact meaning of these percentages.*

FDA Label Image

Figure 4 (Spritam 11)

This text is presenting data about two different groups (placebo and levetiracetam) and their respective percentages, but lacks information on what the percentages represent. Therefore, it is not possible to provide a useful description without additional context or data.*

FDA Label Image

Figure 5 (Spritam 12)

This appears to be a table showing the percentage of patients and the percentage of their response to the drug Levetiracetam as compared to a placebo. However, the values seem to be incomplete and illegible making it difficult to provide an accurate description.*

FDA Label Image

Imprint Marking (Spritam 13)

FDA Label Image

Imprint Marking (Spritam 14)

FDA Label Image

Imprint Marking (Spritam 15)

FDA Label Image

Imprint Marking (Spritam 16)

FDA Label Image

Imprint Marking (Spritam 17)

FDA Label Image

Imprint Marking (Spritam 18)

This text contains information related to a medication called "Spritam" (levetiracetam), which is in tablet form and available in 500mg strength. It comes with a modification guide and dosage recommendation instructions. The medication is intended for oral suspension and each cart contains 10 tablets. It also contains a unique identifier code "DG 348512580".*

FDA Label Image

Imprint Marking (Spritam 19)

This appears to be a package insert for a medication called Spritam (levetiracetam), containing various instructions, dosages, and storage recommendations for use. The text also includes a NDC number and a product code (RL-CTO00354), but it is not clear what they refer to without additional context.*

FDA Label Image

Imprint Marking (Spritam 20)

This looks like a product label or package insert for a medication called "Spritant" (levetiracetam) that comes in both tablets and a suspension for oral use. The label includes information like dosage, the medication's active ingredient, and instructions for use and storage.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.